Exclusive: LATAM Pharma Giant Signs Landmark Supply Deal With World’s Top Cannabinoid Producer

Brain Bioceutical CorporationThe world’s largest producer of natural cannabinoid active pharmaceutical ingredients (APIs) has signed a historic supply agreement with… per-donaduziis one of the largest pharmaceutical manufacturers in South AmericaTo supply Natural EU-GMP CBD API for their ongoing clinical trials and products approved by BrazilHealth Regulatory Agency of.

What happened: “We at Brain Bio have built a foundation with our renowned science team, commercial production facilities and production capacity to produce the world’s purest natural cannabinoid API molecules, allowing our team to grow and achieve global We are thrilled to expand our long-standing relationship with an industry leader in Per-Donaduzzi. We look forward to providing our high-quality natural CBD APIs for Per-Donaduzzi’s clinical trials and cannabinoid products. that we expect will eventually end up in market-authorized prescription (Rx) drugs. Per- Donaduzzi continues to source the most premium ingredients in the world.” Said Ricky BrarCEO and Chairperson, Brain Bio.

“This supply agreement is a landmark moment in the history of the pharmaceutical cannabinoids industry. This result is the culmination of their respective efforts as leading innovators in the space. This makes Brains Bio a valuable partner for Prati-Donaduzzi as they look to lead and expand way in cannabinoid drugs and cannabinoid science.

Milestone deal: For both companies, the deal represents a significant step forward in the development of natural cannabinoid-based medicines in the global pharmaceutical industry.

Brains Bio is a state-of-the-art manufacturer of natural cannabinoid APIs with the largest production facility in the world, built for a global capability to supply customers throughout their drug development lifecycle and subsequent commercialization of future cannabinoid-based market-authorized drugs Was.

The executive teams at Brains Bio and Prati-Donaduzzi have a long-standing working relationship, resulting in one of the world’s most comprehensive pharmaceutical cannabinoid supply agreements to date.

Per-Donaduzzi, a leader in the pharmaceutical industry in South America, enjoys a reputation for innovation and excellence in drug manufacturing and pharmaceutical innovation. The company has the largest portfolio of generic drugs in Brazil and supplies both South American and global markets. They are also the largest distributor of cannabinoid-based medicines in South America, having conducted over five years of research and development in cannabinoid innovation and drug development.

“We believe that quality cannabinoid-based medicines that can be trusted have immense potential to improve the lives of millions of people around the world,” said eder fernando mafisoni, In copy to the Chairman.

“A successful pharmaceutical product requires, among other things, a high-quality, standardized API and a robust supply chain. By partnering with Brains Bio, we can continue to grow in this emerging category and We can ensure that patients are consistently receiving the highest quality API. Brains Bio’s Natural EU-GMP CBD API.”

Brains Bio is equally committed Designed to deliver the highest standard cannabinoid APIs to the pharmaceutical industry, to advance the development of cannabinoid-based medicines and support clinical trials and advancements in cannabinoid science through the company’s science platform and newly opened state-of-the-art production facility.

Global market for cannabinoid-based drugs on the rise: Cannabinoid-based medicines have immense potential to revolutionize the treatment of a wide range of medical conditions. The demand for these drugs has increased rapidly in recent years. The global market for cannabinoid-based drugs is estimated to reach $56 billion by 2026.

Source link

Leave a Comment